Thyroid Gland Disorder Treatment Market Analysis, Trends, Growth and Future Challenges
Global Thyroid Gland Disorder Treatment Market Growth, Size, Trends Analysis - By Indication, By Drug, By Distribution Channel, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25126 | Pages: 1 - 240 | Formats*: |
| Category : Healthcare | |||
Thyroid Gland Disorder Treatment Market Introduction and Overview
According to SPER Market Research, the Global Thyroid Gland Disorder Treatment Market is estimated to reach USD 3.37 billion by 2034 with a CAGR of 3.85%.
The report includes an in-depth analysis of the Global Thyroid Gland Disorder Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. In 2024, the global market for treating thyroid gland disorders was estimated to be worth USD 2.31 billion. From 2025 to 2034, it is expected to expand at a compound annual growth rate (CAGR) of 3.85%. Growing rates of hypothyroidism and hyperthyroidism around the world, caused by autoimmune disorders, iodine shortage, and the aging population, are major drivers of market expansion. Additionally, it is projected that the market for treating thyroid gland disorders would be driven throughout the forecast period by expanding awareness campaigns and improvements in treatment choices, such as precision medicine and tailored drug development.
By Indication Insights
Hypothyroidism led the market and held the largest share of the market in 2024. Hypothyroidism is a disorder that is more common in women and grows in incidence with age. The introduction of new R&D techniques and approaches, as well as the debut of novel disease-treatment products, are likely to boost segmental expansion even further.
The hyperthyroidism category is predicted to increase rapidly over the projection period. It is connected to the increasing prevalence of illness-causing variables such as iodine supplements, autoimmune diseases like Grave's disease, and specific drugs like Amiodarone.
By Drug Insights
In 2024, levothyroxine's market revenue share was the largest. It is due to an increased awareness of thyroid problems. Levothyroxine is the principal treatment for subclinical hypothyroidism and thyroid cancer. Age, gender, smoking status, and other drugs or diseases can all have an impact on levothyroxine dosing and management. With advancements in digital therapeutics and knowledge of hypothyroidism medication, levothyroxine personalised treatment may become possible in the next years. As a result, therapeutic procedures would be more precise, targeted, and accessible.
By Distribution Channel Insights.
Wholesale distribution held the largest market revenue share in 2024 due to high discounts on bulk purchases and fast services. It is vital in the supply chain for pharmaceutical products, including thyroid disorder treatments, and has strong networks and logistics to reach both urban and remote areas. This accessibility helps drive market growth.
The online pharmacy segment is expected to grow notably, with the rise of eCommerce for prescription medications. Convenience, accessibility, and price comparison among vendors are key drivers for online distribution of thyroid medications.
Regional Insights
North America thyroid gland disorder treatment market led the global industry with the largest revenue share in 2024. This is attributed to the high frequency of thyroid illnesses, improved healthcare infrastructure, more public knowledge, and treatment alternatives. Additionally, government and pharmaceutical companies' promotional strategies have supported market growth in this region.
The Asia Pacific thyroid gland disorder treatment market is expected to grow significantly. Key factors include the rising number of elderly people and efforts to create low-cost, efficient products. Promotional strategies and collaborations have also influenced market growth.
Market Competitive Landscape
The thyroid gland disorder treatment industry is competitive, involving large multinationals and small to mid-sized companies. Developing and launching new products with various technologies is a key strategy. Amgen Inc. is a multinational biotechnology business that finds and creates medications for thyroid conditions. To increase market income, they introduced Tepezza, the first FDA-approved medication for thyroid eye illness, and are now comparing Armour Thyroid with synthetic levothyroxine in clinical trials to treat primary hypothyroidism.
Recent Developments:
- In December 2024, Viridian Therapeutics, Inc. reported positive topline findings from the THRIVE-2 Phase 3 trial of veligrotug (veli), an IV-administered anti-IGF-1R antibody for chronic thyroid eye disease (TED). The trial showed promising results in treating this autoimmune disorder affecting eye tissues.
- AffyImmune, a clinical-stage biotechnology company specialising in CAR T-cell therapeutics, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in July 2024 for its AIC100 candidate. This designation recognises AIC100's potential for treating recurrent anaplastic thyroid carcinoma (ATC), an aggressive thyroid cancer.
- Merck KGaA partnered with the Central Board of the Indonesian Thyroid Association and the Executive Board of the Indonesian Medical Association in May 2023 to enhance thyroid disease screening and diagnosis in Indonesia.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Indication, By Drug, By Distribution Channel, By Route of Administration |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Abbvie Inc, Amgen Inc, GSK Plc, Merck KGaA, Viatris Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Pharma (IBSA Group). |
- Global Thyroid Gland Disorder Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Thyroid Gland Disorder Treatment Market
- Segmentation of Global Thyroid Gland Disorder Treatment Market By Indication (Hypothyroidism, Hyperthyroidism)
- Segmentation of Global Thyroid Gland Disorder Treatment Market By Drug (Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds, Others)
- Segmentation of Global Thyroid Gland Disorder Treatment Market By Distribution Channel (Wholesale Distribution, Retail Stores, Online Pharmacy)
- Segmentation of Global Thyroid Gland Disorder Treatment Market By Route of Administration (Oral, Intravenous, Others)
- Statistical Snap of Global Thyroid Gland Disorder Treatment Market
- Expansion Analysis of Global Thyroid Gland Disorder Treatment Market
- Problems and Obstacles in Global Thyroid Gland Disorder Treatment Market
- Competitive Landscape in the Global Thyroid Gland Disorder Treatment Market
- Details on Current Investment in Global Thyroid Gland Disorder Treatment Market
- Competitive Analysis of Global Thyroid Gland Disorder Treatment Market
- Prominent Players in the Global Thyroid Gland Disorder Treatment Market
- SWOT Analysis of Global Thyroid Gland Disorder Treatment Market
- Global Thyroid Gland Disorder Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPER’s internal database
- 2.1.4.Premium insight from KOL’s
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges
5. Market variable and outlook
- 5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER’s Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1.Global Thyroid Gland Disorder Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Thyroid Gland Disorder Treatment Market
7. Global Thyroid Gland Disorder Treatment Market, By Indication (USD Million) 2021-2034
- 7.1. Hypothyroidism
- 7.2. Hyperthyroidism
8. Global Thyroid Gland Disorder Treatment Market, By Drug (USD Million) 2021-2034
- 8.1. Levothyroxine
- 8.2. Liothyronine
- 8.3. Propylthiouracil
- 8.4. Imidazole-based compounds
- 8.5. Others
9. Global Thyroid Gland Disorder Treatment Market, By Distribution Channel (USD Million) 2021-2034
- 9.1. Wholesale Distribution
- 9.2. Retail Stores
- 9.3. Online Pharmacy
10. Global Thyroid Gland Disorder Treatment Market, By Route of Administration (USD Million) 2021-2034
- 10.1.Oral
- 10.2.Intravenous
- 10.3.Others
11. Global Thyroid Gland Disorder Treatment Market, (USD Million) 2021-2034
- 11.1. Global Thyroid Gland Disorder Treatment Market Size and Market Share
12. Global Thyroid Gland Disorder Treatment Market, By Region, (USD Million) 2021-2034
- 12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
- 12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
- 12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
- 12.4.North America
- 12.4.1.Canada
- 12.4.2.Mexico
- 12.4.3.United States
- 12.5.Latin America
- 12.5.1.Argentina
- 12.5.2.Brazil
- 12.5.3.Rest of Latin America
13. Company Profile
- 13.1. Abbvie Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. Amgen Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. GSK Plc
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Merck KGaA
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5.Viatris Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Novartis AG
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7.Pfizer Inc
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Takeda Pharmaceutical Company Limited
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Elexis Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. IBSA Pharma (IBSA Group)
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
- 13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Thyroid Gland Disorder Treatment Market is projected to reach USD 3.37 billion by 2034, growing at a CAGR of of 3.85% during the forecast period.
Thyroid Gland Disorder Treatment Market grew in Market size from 2025. The Market is expected to reach USD 3.37 billion by 2034, at a CAGR of 3.85% during the forecast period.
Thyroid Gland Disorder Treatment Market CAGR of 3.85% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Thyroid Gland Disorder Treatment Market size is USD 3.37 billion from 2025 to 2034.
Thyroid Gland Disorder Treatment Market is covered By Indication, By Drug, By Distribution Channel, By Route of Administration
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Abbvie Inc, Amgen Inc, GSK Plc, Merck KGaA, Viatris Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Pharma (IBSA Group).
The report includes an in-depth analysis of the Global Thyroid Gland Disorder Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
